0001104659-21-063231.txt : 20210609 0001104659-21-063231.hdr.sgml : 20210609 20210507180427 ACCESSION NUMBER: 0001104659-21-063231 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20210507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Synthetic Biologics, Inc. CENTRAL INDEX KEY: 0000894158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133808303 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 9605 MEDICAL CENTER DRIVE STREET 2: SUITE 270 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: (734) 332-7800 MAIL ADDRESS: STREET 1: 9605 MEDICAL CENTER DRIVE STREET 2: SUITE 270 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: ADEONA PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20081027 FORMER COMPANY: FORMER CONFORMED NAME: PIPEX PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20061214 FORMER COMPANY: FORMER CONFORMED NAME: SHEFFIELD PHARMACEUTICALS INC DATE OF NAME CHANGE: 19970730 CORRESP 1 filename1.htm

 

 Synthetic Biologics, Inc.

9605 Medical Center Drive, Suite 270

Rockville, Maryland 20850

 

May 7, 2021

 

VIA EDGAR

 

U.S. Securities and Exchange Commission

Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Dillon Hagius

 

 

Re: Synthetic Biologics, Inc.

Registration Statement on Form S-3

File No. 333-255726                                                     

 

Ladies & Gentlemen:

 

Synthetic Biologics, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-255726), be accelerated by the U.S. Securities and Exchange Commission to Tuesday, May 11, 2021 at 5:00 pm, New York City Time, or as soon as reasonably practicable thereafter.

 

The Company hereby authorizes Leslie Marlow and/or Patrick Egan of Gracin & Marlow, LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 496-2223 or (212) 907-6457, or Mr. Egan at (914) 557-5574 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.

 

  Very truly yours,
   
  Synthetic Biologics, Inc.
   
   
  By:  /s/ Steven A. Shallcross
  Name:  Steven A. Shallcross
  Title:  Chief Executive Officer and Chief Financial Officer

 

 

cc:Leslie Marlow, Esq., Gracin & Marlow, LLP
  Patrick Egan, Esq., Gracin & Marlow, LLP

 

 

 GRAPHIC 2 tm2115646d1_corresp-img1.jpg GRAPHIC begin 644 tm2115646d1_corresp-img1.jpg M_]C_X 02D9)1@ ! @ 9 !D #_[ 11'5C:WD 0 $ 9 _^X #D%D M;V)E &3 ?_; (0 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$" M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# M P,# P,# P,#_\ $0@ + "1 P$1 (1 0,1 ?_$ +T (!! ,! M @)!P($!@H 0,% 0 ! P4! %!@@) (#! >TM>A1_C_ZZKE)&/&+?,G* M4>X> ?JU47@S$X[U45'50U4>:A.44B #K&7DIBTMA6<= !?^!UZF:SS!D?V1 M8.8DY.2#R*L)<(B 1@URT-5-4A0D N4E8<<<8&0N5;R;NS//JJ2!R814!8AR@!#5Z&VCTZ:9:C>F M['KM^955 %>%:PG3QG,>&24/YVF7&)\Q]S&O& 7:-KH61NR( M3$".%%@%&002Z??(F+0IC(AUI[=.SZ2_/KUBL-^I;3O-E V(A*FU+%.PV0HB M39+N*I:N'&.$[G^7:N0AUR@"@5&E.?M@K>&_J \;.==LSEQ8!O!S,K6LLFTNRVY>-=0U MS6T^/T(VEXQT4JK8YS!3J%*Z'WJRU] )&8/K@E9]P4-R22V1]$&^0QQ(43$V MF$I1,7< T$0ZA7VT'6HWJ#:0KWI"<'^\9154W[/\H:OBHL'*IDP5-[Q * U4 M+4Y$R[1,*BA1H%" '75J7 I91+&,#@*)K$!L7F?C:_["S?J=B7!;L[*-Y9T>=(AN=M3KM@V%, MQ5 2' /:&MJKMRJ)D)7[V/JX]D:M+=O.U14G\,R]OMAK)%#"@:227_ .XT0L"D\H*E'SI640AV+Z3D5DF;)@U7=N7:AC=IJU;IG6\G,F\BV.2 M7&2>-F1>.SBRKZ?VK ,K\4;+&O>':BL*%VPQT?ACG8)A0#=0$P:L=8+) [8V M*&M%2E1' CZH-$HF ,K4INO2M0 *]*TZ!K%&\5D8JB/LC7@ULNU+@NM]T9V M]&.9-41$0 Z;6YZ#9VVZO<5PTZ*9K4F)"1[Q M';VB#.W;>[>;RQ;F?Q'5R'L..$X6_?&5+H?\2IO([]\/S+)-P/&Q>VX4VL(] MT[[$:T0 #?<&(V -P%IU'3&]];^W,OI5'&'8;>ZG6GZ65=WI$ .:2H$#C+C).4/$^MK2_P#O M(_XQ?Y]36_J_M'[[?_4C_5$?OY=K/Z*_8?W1J76#Q?Y9>F]GW,N?.!MKXKYY M8%OY>.^M[?=W)$3N6+768-S*N&"$FF"[DR[HHA1/?4P4J%-.4NU[3?6D(9_M MC/)/A!/IXRAL]NIV[:X36-MOI'W@%#'CC&2V!,XTYA\=>=6:^ )LK<-N=#5^ MUN[/%@HNO)/'=R6BQ74-;#9DH4K-"+FTVZA!\N0@@J4!'WAT/8M[M/4MF[J4 M]3.*D"HZM)E@3,2EWP2?:%Q8(L\V'9?[?A^J%NO>9_*[)'%?@?;&'N:N>UN5 MF:\UW78&0X LRV57B&BDNSCS*RY#-3O&C6/,9,S/<(CVP/7Q'1*K8H65* IF M>6$@A6@8YP+IMQ7%2O)J?=YC:BV?$9S3A,X\3W0PGU*#\VN'^?O3^L+&G.+, MCR2SH[M[&=U)W$Y:O8$D]#D9LW=W/8\@D.^<2:KLYE2" I&,4*AH13/V]V9- M,U($_9!RXP9=MMYJDS17U")C^HI,HKBYSFCQV]5)?@'>'-G+&5K1Y&82N.73 MO262:A,V%/R<0\=!*VPT ?+-#PBB8B1-("AVJ '71FCI[96[>J:T4K27$K20 M= !PGA.61XP,KEW2CNU'2BLJ%);0I*QS"0J?%6.*APG&-_\ Y\\ WJQY"\T[ MQ_/:\U[?Q)E2]+*NNRC)-@B,R2:Q)YHUONY5PKV9$#I"KVQJ8BAQIH+>'&V] MO4P;:2'UDG4!(X*]I[((6%+JMU5#U4ZI="$8)49I]T9 X9XP&W!3!7(_)N'/ M4TR1@WE=>G'2*PQF3(MV?(["2:F<7U.V^5Y,(GG)]8Q%V[4C%N*1$4AH>H5Z MUT7N-&E[X:7$B;JY$2S\(S[H$4U)6LU=RKD/N)ID("DIU$ 2,O",A$NY*]8W ME<_]-#A;'I9.>6'EW/&0KEQ_DO.,3%JRK;% -V):Y+7)*$G3I$L09X2C=9W6XYM5S34.^8UK 45^+,2QG..^- M/)#D1D+D+?\ PIL;FKR S+@G->&+EDH[/%Y61-0=[8\O"VH)Y/RT1&O)9H@< M[>2(T,U$1,!:*E *ZP!-NM]2MAVG;4ZBH40-((D3ID<,DY@2PCT5%<\5(34. M^*WA<]1]Z6?I[\XFCT!^-.2;SXP\L+M@N3N4<>QADQ "MU"GNMX1+MJ!TVD$?:.@5W?;-P :;2$E0P D)3C)M6EK4V"MJZZH< M6XA:I%2B2!H!D">^!SQ-ZH'+W"'IT\N;A?YDO')>8$.5S#C_ (MOR^5PE5[8 MCE%7+&2>@F=,J+551%(%2%'X%?#1J[T#"E4JTLI'@),DYX_:[8JBO2G+'J9< M*7=$B09&?;.><- PAPT]5+#67.(>7+1YE7[G_&]_K6_.\H[:R3/HEA8.)FV3 M&170L]@JD[,L3<\,5.FWM@2@=!T)K'[=Y=;09;2Z 1@D3]/UP0VHS=*M\*>J M'EH..*R1#BO4#N5U"<=)XK-51!>9F(:/%7XT3H+*G,L!# (&]U)/K[H!UTPW MYS[M<*?I%54U %I0XH!:DA0( 4DY@R ],/3^6';;%PZNV]NOTKH 5J7KD0D! M"I'$2!G*4X!_#CI+.'#N^\410D-=MARQ[CAVACT=/&S4_FRF;(_&H"PD$H 7 MVCIN>R CJ3\MJ]EV-Y3]_'-F"H*4DS&6G4H=WACMN^VG]@_,8S>UMRVK.G3S M"DZ0"#.2I!$TGOPXPNHTN\;&517*NS=-5P.LBLF*;MFY*KN424(< ,4R2J?N M^T-,#N=JNVTK\G:==3!N_P!)4"H4XI"DK*,@G40%:9X@2 GQA\;%CVYO>A7? M*9Y%1;GZ8M!04AO%X"2IP* "@R0)G/Q-B1]<3QB#E=%9-(TPQR+:,)V(N!,8Z+O8Z21)*- M<+%VM7"[DY#*D6%80#?6NNK='.N@WT#T^ZDV>WN^98<(?>IRISF >#QO+(G, MX83GE'*NKW1/\B5 W]T^KJL,LNI"F$.@-D*,L$-('KQP@8\YXXEL(9$?VH^< MK+1XE3E;8E! 3IR4$N85T025,%#JH'(4IOT#IMV_>DESZ.[L%-YY"?>G)RSLV)QKE.2 M2E9VRLXP"UQN8F2(@1 92.E$CG%9R"9*!X= U/\ T5\LJ6@*EM!5/*4QZL8A MNK-O//&=(9#MP$%3Z>OI]H^G;$\C>1?)[-$)D+)V:E7-T9GO<[,(*S8&%3%1 MS(E;MC%&J0B>HCMJ(!K1OMSJKNGR]OGIR2!/L_9!&P6CX2K748PE#T@^)^(L MU^K/R8Y'X=6-=O&#!EW7!.XPN8[98MM2=]7NJ](#2 0EV^PPYA5AA 4>((2-4(NV69FLOU0XT!^.LY?XB1#5O4Q]-_E; MS,Y0X2R7C3.6&K)M;CP_B;HQ]:URQ:SFY$[M,]2>RRDT)%@4=,9)N3[H #IT MTC+1N.VH4+5]*/1Y5G+::?J(IJ"5)FX8+F(D00Z&IK)>]WT:JN@+$RVV MYV$2\(RC::VK7FDK*(_BN,) Q'''LB);5]!'/JO&&WN/V0.0.,8_(F!K^-DO MC#=%M1"YW,)*2C@LA$(Y'3:\MV)U]Q!Q6O#[.,@)&6?&&=<1^,/J"VUD=.6YD\A8PQM"VW,SSR39E9HW$YN5-NC()O2 4#F$OQB;;UTF7-QTKUT<+,@>:2 >' MB[SV80LK7LNY^5-2X%$)H=&&.0'= ^\&_3HYW\&Y7D?CK'F?,13V#\D(7[6@ES70SR%/[4HV7FTQ4(LI&10*"5?;4%-M?;HE7WFV%]I;D@N8,^.>6>4 M8++8KD[MNOHQ^(M:@,?\(&$N,Z;I05@MAV144Q1('CUTHZW>%K6ADHD5)1+LXYYP+LW36 M[M64ER8$@<\/1.4%G@?TZ_4.'./'F>Y>\V8"3Q=QI;IM++L#% NK9DL@-H\B M*$:E?J952!-E2011(?<4P"4H!I,U=ZM3VLM(1S53[L_7"PVOMJY6_P#%F?7, M>V4-9YWV4_N_CI>C6+ 3OH%%&>;-42]Q50K$3J'23 *B!#(J4 /'IIL_S'V0 M;AZ;U%&A"54O^Z>Q/;+T]L. Z$[AK+1U3MU*3I9JZA+*U3/A29DF>7 9X1KM MX@SQ=N&[SAKZM=R**[0Z*+V.R)CII+NFZ*IB)F464.(%V_;73 MMMQ;+Z5]<[W3[CIJAJDW8]3-AX2:05)..*G%:B03E*&'6:^]6N@=GJ=MN4KU M;:4U;JFU!3B]!D 9AI,@) 8Q(V9N 6-,=8-N*[8ZZIA6Z+1A2RB\DJX*#.3< M$*43(E;?AN$7)AJ00'W2AK:W5\L5EV-MER]L586$IG,J:$^["!>R?F2W#OO> M;5BN5(I+:W=!3ITH11,0.@ HAU' MMG* U >@]=,)O[EYMEV;O%JQ2+N+KE&K6W0#LB+A\JJW[8$,< WG!19"H_;I^WS M'6IKJ'T]L:6TCS.E)4>))T=OHB/_ *%U;&R.LN[Z(?\ :4;Y"1P$TE60]/", MF_&T/ O\&I410TB3J"!.& I 0)(P$8I>5C6OD*VINS;V@6%RVM<;)>,G(.42 M,NPE(]P&U9JZ2J&])0O00J&B5-5U-&XEVE64.)R(X<(\<0EU.EP33&$8KP7B M3 ]LDLS#>/+7QM:Y5EEPA;5C$8UF9=6@F65*F G65Z=!.(B'LU8XXJYI<-<> M8I2CG_"4#Z>WVZW58019NT!6 M6;L'Y(/Q$B9/?*?#N@VB6_<0\QSRZS64):J>%BL"/3G.$* M,M\\36[1DA.*0/1*%0'J< &E=*Z]T-:VZ^FG)2T[(JE*1(RG"$9JK4ULA>E" M19\B[D(&_63CZOOB1N*YWA'A[37TP;9<8:-6 M$ )5-6HJYJM6$Y>[*"5QU-/8/E[FRW9J$O%)C>#2S'MMR814BXMNL?$$3D/] MR*56/9E[X= 0K2H]:Z4U$U7.WU=-6**J=M*2@&4DF6,I0BZTVM.TZ.Z4C:1 M<5*<2ZO'4I*?"@$3EAW#TP.=SVED(W-MH\0A;W(X_,*-?L;F36E"VPGC(8)5 M"08%-W4V2I@?C4P&((B(^.DQ?'+ZC9K6F MW$AA9$R1_-GAD>SAE'IR6A[Z8T:M7A.F0E*4Y9^J"^N:+N%7E+B>518RQ[;0L&\F[Z03*L#% MJZ5=-G#9&2 X%V* 4I@+N\0T=30UKC2'*Q16L)P)E'+K#46IK:ES/+1YM-6= M"L9Z D80+]O0,@ES1NM:Y+*R;)3LC??S:S;ZCW[]M84+8P0/:6;2*(K@Q\CA&KM)T" M@J@HG3PUHUC-Q:KD)0HA$Q/+NC-M5ZTJLCQK4)+@!D3/#/@)3AGSV,:R<>ZC MI-%-VP?-%T7Q#@4R:J*Z(H*(G-41.L(#3ITKI:5MB9O5C!REZ01'(6+K76[<(J:%906W$J3+ C$'VQJT\Y.+5Q\=;\D9J,BGSK%=P/5 MW\++MR*+!;RRZHN%(IXL0#$9IB8VX%#AU#I74:O7GH>YM!:G-ITXIJ/42-$B M,<3[RE&)A/E:ZZ6ROM@MEVJ/[]20E8,YX83P3*1, \6X2B;NINB@JD9,Y3IF M,"K<]/NS(.2B!C (!7< U =-CI*)RV.LW)MO1?D. %W[6DJ>XKUMX6.[53CU,4 :"!*0$I8)'UQR?:G0#I]1;A-^ MH+33LW$+*N8"N;=J M-QO.A*Z=LI'=J$N$_J,;2#'BN+PF +?N,&SBR\+PK9^DR4,)CR=X"U,D956A M@,9HS56,HGU^( K74J]BZ?VM[:U,S=V$.OLH&FC_IICA/+$9AI?04CFJBHM MEZ=/U]?X]7,<9=IC3JO>3I]^<8XO\F\T?O4\QM4W[NYLW4#X_P"AYBE.W7WO MV="6/)?$?#+G3,$:KS_E#/5HT^J7&+D?*51^#\,FW=X[-Q=N[=U_$I6OMT8J M>3CSOI@>?-^4:E/RTLS5C'NMY+NI;=V_YV:?W%?';[GVZ&UOD_,?S)< MWUP6MG.\D9ST\.S]T4./*53[E*=\>QWMW;[G>#=^)[O<[E-M>OV=-%_[;6-< MM7+X]D:5D\U*HY.J7CR^F*5/+T7V[JU^^V;^Y38'XE/>ILI6OLI77E5R.2G5 M+3* %-S?A]7R9Z.8=7LCU;^1WH=SQV%IOW]O=3[NE?<_53V_IT'1R?,C3[O_ M !*#]KYGPEK7.6C#T1<+>1WEI^+M'X]]?9OW[^OM-6U_)Y@^]QC=H^; MI\$Y1W3MT#=\79\ ^&ON5KX4]NB:_,:6_+9<92R@>QI\T[S/?PB-LK M?EO](RGYJ?(OH3R2WSOZD[/RSR_;-^-YGW>]N^'^E7PTF]W_ )>^%*_,.G3I M.<_V?1!K;7YQ^/L_ESF]SO_L[NFN"U M_P +\^G5^%,=O;#HG.9\/<^&2Y^DR]A[<(V#?2X_='\R]^A/F7YX>72^=?6_ ME_G6S87?\H[/^W=GM>/9Z_;J0OH9^1O(-:/_ &&D9ZOH]<0[?-W^L_(>\]+\ MM^:$N7H]6OCZ.$X>$EN[H]S=NJ?;W*UIN#=2OLKX?R:=6OE>6/+_ I?LPB/ 6]'FM>/XGVLHO_N_T:3W\CN@CX8__V0$! end